Edition:
United Kingdom

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

52.60USD
15 Dec 2017
Change (% chg)

$-1.05 (-1.96%)
Prev Close
$53.65
Open
$53.71
Day's High
$53.80
Day's Low
$52.15
Volume
1,417,256
Avg. Vol
590,314
52-wk High
$57.50
52-wk Low
$26.26

Chart for

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $3,262.29
Shares Outstanding(Mil.): 64.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

09 Nov 2017

UPDATE 1-Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

09 Nov 2017

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

09 Nov 2017

BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes

* Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024

07 Nov 2017

BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051

* Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051

07 Nov 2017

BRIEF-Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program

* Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program for the treatment of duchenne muscular dystrophy Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Sarepta Therapeutics signs exclusive global collaboration with Duke University

* Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD)

31 Oct 2017

BRIEF-Sarepta Therapeutics appoints Chief Scientific Officer

* Sarepta Therapeutics appoints Guriqbal Basi, Ph.D. as Chief Scientific Officer Source text for Eikon: Further company coverage:

25 Sep 2017

Sarepta's shares jump on new DMD drug's promising trial results

Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.

06 Sep 2017

UPDATE 1-Sarepta's shares jump on new DMD drug's promising trial results

Sept 6 Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.

06 Sep 2017

Earnings vs. Estimates